Even though Advair’s main patent expired in 2010 and ... Mylan obtained approval to market the generic dubbed Wixela Inhub in three strengths: fluticasone propionate 100 mcg/salmeterol 50 ...
All three strengths of the competitor branded as Wixela Inhub will be offered at a wholesale cost of 70% less than Advair Diskus and 67% less than GSK’s authorised generic version, which ...
Introduction: The incidence of asthma exacerbations in patients receiving salmeterol/fluticasone propionate (Seretide™ or Advair ®) is low. However, when asthma control deteriorates ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback